Brief: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To Nexiguran Ziclumeran
25/11/2024 12:41
Nov 25 (Reuters) - Intellia Therapeutics Inc NTLA.O :
* INTELLIA THERAPEUTICS ANNOUNCES FDA REGENERATIVE MEDICINE
ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO NEXIGURAN
ZICLUMERAN (NEX-Z) FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN
(ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY
Source text: ID:nGNX3sVLDg
Further company coverage: NTLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)